Contains Nonbinding Recommendations

Guidance on Imatinib Mesylate

Active ingredient: Imatinib Mesylate

Form/Route: Tablets/Oral

Recommended studies: 1 study

Type of study: Fed
Design: Steady state, two-way crossover *in-vivo*
Strength: 400 mg
Subjects: Patients already receiving a stable dose of imatinib tablets, 400 mg.
Additional Comments: Recruitment efforts should be targeted at patients for whom a titration away from the 400 mg dose is unlikely, such as patients with gastrointestinal stromal tumors and patients in their first three months of treatment for chronic myeloid leukemia (CML). Patients should be screened for hepatotoxicity prior to enrollment and the protocol should include procedures to monitor for hepatotoxicity during the course of the study. Concomitant medication with drugs known to be inhibitors and/or inducers of CYP3A4 family should be a protocol exclusion criterion.

Analytes to measure (in appropriate biological fluid): Imatinib in plasma

Bioequivalence based on (90% CI): Imatinib

Waiver request of *in-vivo* testing: 100 mg based on (i) acceptable bioequivalence study on the 400 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times:
Please note that a **Dissolution Methods Database** is available to the public at the OGD website at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.